- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
340B: Additional Burdens
In addition to the challenges surrounding the 340B Drug Pricing Program previously discussed by the managed care stakeholders during this Oncology Stakeholders Summit, Spring 2015 series, Ted Okon, MBA, describes some other ways the consolidation between clinics and hospitals impacts patients.
Mr Okon notes that when consolidation takes place, cancer patients who are in the middle of their course of treatment are sometimes burdened by a sudden increase in the price of their treatments. In some instances, the cost of treatment may rise by 50%.
In addition to being impacted by rising fees, adds Mr Okon, patients are being asked to split up combination therapy, especially in diseases such as multiple myeloma, where patients are treated with a combination of brand drugs and generics. Patients are administered certain medications in a clinic setting, but are then directed to travel to a hospital to receive the rest of their medications so that hospitals may take advantage of the financial benefits of the 340B program, explains Mr Okon.
If the issues surrounding the 340B Drug Pricing Program are not addressed soon, the introduction of oversight will hurt patients, notes Scott Gottlieb, MD.
Balancing Cost and Quality in Oncology: A Value-Based Care Perspective
January 30th 2025Travis Brewer, vice president of payer and public health strategy/relations at Texas Oncology, shared that value-based oncology care can achieve both cost efficiency and high-quality outcomes through integrated multidisciplinary teams, flexible payment models, and targeted treatment approaches.
Read More
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
January 23rd 2025On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Listen
How FcRn Blockade Targets Myasthenia Gravis Autoantibodies
January 29th 2025In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.
Read More
